These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27702619)

  • 1. Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project.
    Ritchie K; Ropacki M; Albala B; Harrison J; Kaye J; Kramer J; Randolph C; Ritchie CW
    Alzheimers Dement; 2017 Feb; 13(2):186-195. PubMed ID: 27702619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0.
    Ritchie CW; Muniz-Terrera G; Kivipelto M; Solomon A; Tom B; Molinuevo JL
    J Prev Alzheimers Dis; 2020; 7(1):8-13. PubMed ID: 32010920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility.
    Mortamais M; Ash JA; Harrison J; Kaye J; Kramer J; Randolph C; Pose C; Albala B; Ropacki M; Ritchie CW; Ritchie K
    Alzheimers Dement; 2017 Apr; 13(4):468-492. PubMed ID: 27702618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol.
    Solomon A; Kivipelto M; Molinuevo JL; Tom B; Ritchie CW;
    BMJ Open; 2019 Feb; 8(12):e021017. PubMed ID: 30782589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive Functions as Predictors of Alzheimer's Disease Biomarker Status in the European Prevention of Alzheimer's Dementia Cohort.
    Terrera GM; Harrison JE; Ritchie CW; Ritchie K
    J Alzheimers Dis; 2020; 74(4):1203-1210. PubMed ID: 32144988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The European Prevention of Alzheimer's Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer's disease dementia.
    Saunders S; Gregory S; Clement MHS; Birck C; van der Geyten S; Ritchie CW
    Front Neurol; 2022; 13():1051543. PubMed ID: 36484017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept.
    Epelbaum S; Genthon R; Cavedo E; Habert MO; Lamari F; Gagliardi G; Lista S; Teichmann M; Bakardjian H; Hampel H; Dubois B
    Alzheimers Dement; 2017 Apr; 13(4):454-467. PubMed ID: 28188032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project.
    Ritchie CW; Molinuevo JL; Truyen L; Satlin A; Van der Geyten S; Lovestone S;
    Lancet Psychiatry; 2016 Feb; 3(2):179-86. PubMed ID: 26683239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials.
    Vermunt L; Veal CD; Ter Meulen L; Chrysostomou C; van der Flier W; Frisoni GB; Guessous I; Kivipelto M; Marizzoni M; Martinez-Lage P; Molinuevo JL; Porteous D; Ritchie K; Scheltens P; Ousset PJ; Ritchie CW; Luscan G; Brookes AJ; Visser PJ
    Alzheimers Dement; 2018 Jun; 14(6):837-842. PubMed ID: 29604264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach.
    Posner HB; Cano S; Carrillo MC; Selnes O; Stern Y; Thomas RG; Zajicek J; Hobart J;
    Alzheimers Dement; 2013 Feb; 9(1 Suppl):S56-60. PubMed ID: 23391006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Late life depression or prodromal Alzheimer's disease: Which tools for the differential diagnosis?].
    Gasser AI; Salamin V; Zumbach S
    Encephale; 2018 Feb; 44(1):52-58. PubMed ID: 28434642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
    Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
    Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria.
    Wimo A; Ballard C; Brayne C; Gauthier S; Handels R; Jones RW; Jonsson L; Khachaturian AS; Kramberger M
    J Intern Med; 2014 Mar; 275(3):304-16. PubMed ID: 24605810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline.
    Amieva H; Mokri H; Le Goff M; Meillon C; Jacqmin-Gadda H; Foubert-Samier A; Orgogozo JM; Stern Y; Dartigues JF
    Brain; 2014 Apr; 137(Pt 4):1167-75. PubMed ID: 24578544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal normative standards for cognitive tests and composites using harmonized data from two Wisconsin AD-risk-enriched cohorts.
    Jonaitis EM; Hermann BP; Mueller KD; Clark LR; Du L; Betthauser TJ; Cody K; Gleason CE; Christian BT; Asthana S; Chappell RJ; Chin NA; Johnson SC; Langhough RE
    Alzheimers Dement; 2024 May; 20(5):3305-3321. PubMed ID: 38539269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome.
    Startin CM; Hamburg S; Hithersay R; Al-Janabi T; Mok KY; Hardy J; ; Strydom A
    Alzheimers Dement; 2019 Feb; 15(2):245-257. PubMed ID: 30503169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer's trials.
    Nuño MM; Gillen DL; Grill JD;
    Alzheimers Res Ther; 2019 Nov; 11(1):92. PubMed ID: 31775871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.